Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | MYC | P01106 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9262225 | 0.82 | GAA (0.55) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL11564833 | 0.81 | ALDH1A1 (0.43) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL15636976 | 0.81 | ALDH1A1 (0.43) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL5853684 | 0.78 | ALDH1A1 (0.51) | TTRALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL317655 | 0.77 | ALB (0.49) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL3729139 | 0.76 | TSHR (0.46) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL6512006 | 0.76 | AKR1C3 (0.51) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL28755352 | 0.76 | TLR9 (0.45) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL11563899 | 0.75 | GAA (0.47) | CA12CA1CA9ALDH1A1ALOX15 | |
| SCHEMBL30740619 | 0.75 | TTR (0.58) | TTRALDH1A1ALOX15MAPK1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114173877-B | Novel therapeutic vectors and prodrugs for the treatment of cancer | 施科友智能化学疗法公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-1827239-B1 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | PURDUE RESEARCH FOUNDATION (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2452695-A2 | Positron emission tomography imaging method | Purdue Research Foundation (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8093405-B2 | Formation of 18F and 19F fluoroarenes bearing reactive functionalities | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2012-01-10 | — | — | US | disclosed |
| EP-2310362-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | University Of Newcastle-Upon Tyne (GB) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009138763-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | US | disclosed |
| EP-1827239-A4 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | PURDUE RESEARCH FOUNDATION (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20070276231-A1 | Positron Emission Tomography Imaging Method | PURDUE RESEARCH FOUNDATION | 2007-11-29 | — | — | US | disclosed |
| EP-1827239-A2 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | PURDUE RESEARCH FOUNDATION (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006071754-A2 | POSITRON EMISSION TOMOGRAPHY IMAGING METHOD | PURDUE RESEARCH FOUNDATION (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | RARB, RARG, RARA | TTR 1542/4885CA12 316/4885CA1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.